An observational study in Breast Cancer, sponsored by Mayo Clinic. Completed at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-02.
Sponsored by Mayo Clinic · Observational
Determining if Megakaryocytes and Platelets are Harmful or Helpful in Breast Cancer Cell Metastasis
The purpose of this study is to determine how megakaryocytes (cells in the bone marrow responsible for making platelets, which are necessary for blood clotting) affect the survival and growth/division patterns of breast cancer stem cells, and the effects of breast cancer cells on megakaryocyte survival and function. Through chart review, the study team will look at the relationship between different blood components and different breast cancer diagnoses.
12,544 studies on the registry are indexed under Breast Neoplasms; 2,892 are open to participants now.
This study's enrollment of 23 is below the median of 184 across 2,642 observational studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →Mayo Clinic is the lead sponsor of 3,218 studies on the registry; 670 are open to participants now.
Of its 445 completed or terminated interventional studies of FDA-regulated products, 313 (70%) have results posted.
Counted across the registry records on this site, refreshed daily.
For the prospective study: 20 women after biopsy for suspicious mammogram findings, 10 women with newly diagnosed metastatic cancer.
Subject population (children, adults, groups): Women undergoing biopsy or suspicious mammogram finds and newly diagnosed female metastatic breast cancer patients.
Cohort 1-Biopsy negative
Cohort 2-Biopsy positive for carcinoma in situ (ductal, lobular, or other)
Cohort 3-Biopsy positive for Stage 1, 2, or 3 invasive carcinoma (ductal, lobular, or other)
Cohort 4-Stage 4 Metastatic Disease
Exclusion Criteria:
Cohort 1-Biopsy negative
Cohort 2-Biopsy positive for carcinoma in situ (ductal, lobular, or other)
Cohort 3-Biopsy positive for Stage 1, 2, or 3 invasive carcinoma (ductal, lobular, or other)
Cohort 4-Stage 4 Metastatic Disease
Female age 18 and above with negative breast biopsy
Other: Blood draw
Females age 18 and above with any subtype of breast cancer (ductal, lobular, or other)
Other: Blood draw
Females age 18 and above with any subtype of breast cancer (HER2+, ER/PR, TNBC, BRCA1 +/-, other).
Other: Blood draw
Females age 18 and above with any subtype of breast cancer, including metastases
Other: Blood draw
10-12mL of blood will be drawn one time, unless a redraw is needed, in which case up to 24 mL will be drawn (10-12 mL each draw)
Platelet Counts
Measure of the number of platelets in the blood, reported as platelets per microliter of blood.
Time frame: Baseline
Mean Corpuscular Volume (MCV)
Measures the average size of red blood cells, reported as femtoliters (fl).
Time frame: Baseline
Lymphocyte to neutrophil ratio
Ratio between the neutrophil and lymphocyte counts measured in peripheral blood.
Time frame: Baseline
Levels of tumor educated platelets
Number of tumor educated platelets, measured by the analysis of cell surface markers for expression of certain markers such as VEGF, PDGFR, MMP1, TGFb, and or other cell adhesion molecules.
Time frame: Baseline
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mayo Clinic